Updated date - Dec 12, 2019

[261 Pages Report] The market for sleep apnea devices is expected to grow from USD 4.5 billion in 2019 to USD 7.5 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 10.7% during the forecast period. Growth in the sleep apnea devices market can be attributed to factors such the large pool of undiagnosed sleep apnea patients, growing awareness about the ill effects of untreated sleep apnea, growing usage of oral appliances, technological advancements in sleep apnea devices, considerable venture capital funding, and the increasing number of companies venturing into sleep apnea and oral appliances markets.

By type, therapeutic devices segment is expected to grow at the highest rate during the forecast period.

An increasing pool of undiagnosed sleep apnea patients, the improving reimbursement scenario for these devices, and the growth in usage of oral appliances are some of the key factors which are expected to fuel market growth during the forecast period.

By end user, sleep laboratories & hospitals accounted for the largest contributor of the sleep apnea devices market.

The portfolio of devices used in sleep laboratories and hospitals is limited mainly to diagnostic devices, such as clinical PSG devices, actigraphy systems, and tabletop pulse oximeters. There is a growth in the number of sleep labs and sleep tests performed using a clinical polysomnography device globally, as these tests are being considered the standard diagnostic test for sleep apnea over a long period of time.

North America accounted for a significant share in the sleep apnea devices market in 2018 while the Asia Pacific region is expected to register the highest growth during the forecast period

Factors such as the rising prevalence of sleep apnea in the region, increasing awareness initiatives taken by the government and organizations, adequate funding and growing usage of oral appliances in the region is driving the growth of the North American sleep apnea devices market. However, the high growth rate of the APAC region can be attributed to the increasing prevalence of sleep apnea disorders in this region, strategic agreements of global market leaders with regional players, the large undiagnosed pool in countries like India, and initiatives taken by the government & other private organizations to raise awareness regarding sleep disorders.

Driver: Large pool of undiagnosed sleep apnea patients

Although highly prevalent in the elderly, sleep apnea affects people of all ages and is one of the most common sleep disorders across the globe. The health impact of sleep apnea is quite substantial but under-recognized.

Worldwide data suggests that sleep apnea impacts more than 936 million people worldwide, which is nearly 10 times greater than previous estimates (Source: ResMed). In the US alone, around 22 million Americans suffer from obstructive sleep apnea (OSA); of which, 80% of moderate and severe OSA cases are undiagnosed [Source: American Sleep Apnea Association (ASAA)]. In the UK, OSA affects an estimated 1.5 million adults; up to 85% of these cases are undiagnosed or untreated. In countries with huge population bases, such as India and China, the diagnosis rate of OSA is <1% (Source: Press Trust of India, 2017 and China.org.cn).

Another study from ResMed states that up to 4% of all children suffer from sleep apnea, which is commonly misdiagnosed as attention deficit hyperactivity disorder (ADHD). Also, up to 20% of children who habitually snore suffer from sleep apnea as well (Source: ASAA). This leaves a colossal pool of undiagnosed individuals suffering from OSA.

With increasing obesity worldwide, the global sleep apnea patient pool is also likely to grow in the coming years. Approximately 40% of people who are obese have OSA, while ~77% of people who are morbidly obese have OSA (Source: British Lung Foundation, Toolkit for commissioning and planning local NHS services in UK, 2015). According to the WHO, since 1980, obesity has more than doubled across the globe. With at least 2.8 million people dying each year from being overweight or obese, obesity has reached epidemic proportions globally. In European countries, the number of obese individuals has tripled over the last two decades while in the US, nearly a third of all individuals are obese or overweight. Changing lifestyles also contribute to the rise in obesity prevalence across the globe, which is likely to result in a significant increase in the sleep apnea patient pool. This expanding pool of patients offers high growth opportunities for the sleep apnea devices market.

Restraint: High cost of CPAP machines

In most developed countries, the cost of a CPAP device is either reimbursed or provided by medical insurance companies. The main reason for non-adherence is non-acceptance on the part of the patient, mainly due to the mask causing discomfort or claustrophobia. However, conditions are different in most developing countries, where insurance access is minimal and insurance companies usually do not cover the cost of a CPAP device.

In countries like India, CPAP is not covered by private insurance companies. Only some government employees are able to be reimbursed for CPAP therapy, and that too reimbursement ranges from 30% to 100% depending on the reimbursement rules of various government offices. CPAP is generally an out-of-pocket expense for most of the Indian population. This is a major limiting factor for therapy adoption in these countries.

Similar factors affect the CPAP compliance rate among patients in other South Asian countries as well. For instance, in Singapore, the cost of a CPAP machine is substantial, with an auto-titrating CPAP device costing between USD 1,100�USD 1,500 (1,500�2,000 SGD approximately), which would be nearly half the median monthly income of the average Singaporean worker. Thus, high CPAP device costs act as a restraining factor for the global sleep apnea devices market, especially in developing countries.

Opportunity: Increasing focus on telemedicine and mHealth (mobile health)

Several studies have reported that a main predictive factor for long-term CPAP compliance is patient adherence in the first few weeks of treatment. To improve compliance, support and follow-up during this period must be prompt. Telemedicine offers this kind of assistance since long waiting lists make it difficult to provide such support. Several studies suggest that patients in the telemedicine group expressed high satisfaction with their care. They especially liked the convenience of a live video visit with a sleep doctor.

Obstructive sleep apnea is a highly prevalent chronic condition, and telemedicine could play a vital role in the different phases of its management. In the future, using new devices capable of signal acquisition and analysis is expected to refine obstructive sleep apnea diagnosis; even smartphones� built-in sensors could offer improved comfort and the possibility of home sleep monitoring. Continuous positive airway pressure titration could be performed with wireless devices, whose parameters can be changed remotely from sleep centers. Finally, the follow-up phase could be specially improved by using remote continuous positive airway-pressure data, self-management platforms, and mobile applications for patient feedback. Moreover, instead of replicating traditional visits, mHealth can provide shorter and more frequent assessments; alarm systems on the patients� devices could alert physicians and mobile applications with simple questionnaires may help on follow-up. The sleep apnea market is likely to show positive growth owing to these potential benefits offered by telemedicine and mHealth in improvising sleep apnea diagnosis and management.

Scope of the Report

Report Metric Details Market Size Available for Years 2017�2024 Base year considered 2018 Forecast period 2019�2024 Forecast units Value (USD) Segments covered Type, End User, and Region Geographies covered North America (US & Canada), Europe (Germany, UK, France, Italy, Spain, & RoE), APAC (Japan, China, Australia, & RoAPAC), RoW (Latin America and the Middle East & Africa) Companies covered ResMed (US), Koninklijke Philips (Netherlands) and Fisher & Paykel Healthcare (New Zealand). Major 12 players covered.

The research report categorizes the brain monitoring market into the following segments and subsegments:

On the basis of type, the sleep apnea devices market has been segmented as follows:

Therapeutic Devices

Diagnostic Devices

On the basis of End User, the sleep apnea devices market has been segmented as follows:

Sleep Laboratories and Hospitals

Home Care Settings/Individuals

On the basis of Region, the sleep apnea devices market has been segmented as follows:

North America US Canada

Europe Germany France UK Italy Spain RoE

Asia Pacific Japan China Australia RoAPAC

Rest of the World (RoW) Latin America Middle East & Africa



Key Market Players

The major vendors in the global sleep apnea devices market are ResMed (US), Koninklijke Philips (Netherlands), Fisher & Paykel Healthcare (New Zealand), SomnoMed (US), Oventus Medical (Australia), Compumedics (Australia), L�wenstein Medical (Germany), Drive DeVilbiss Healthcare (US), BMC Medical (China), Braebon Medical (Canada), and Panthera Dental (Canada). The dominant players, which includes ResMed (US), Koninklijke Philips (Netherlands), Fisher & Paykel Healthcare (New Zealand), together accounted for ~94.4% of the global sleep apnea devices market in 2018 while the other players together accounted for ~5.6% of the market, owing to their substantial product innovations and expansion in business strategies across the globe.

Recent Developments

In 2019, ResMed (US) launched AirFit N30i, its first top-of-head-connected nasal CPAP mask, across the US with a newly designed nasal cradle cushion that sits just under the wearer�s nose.

In 2016, Koninklijke Philips (Netherlands) launched its Dream Family solution which comprises of a DreamWear mask, DreamStation PAP device, and DreamMapper patient engagement app.

Key Questions Addressed by the Report

Which type segment will dominate the sleep apnea devices market in the future?

Emerging countries have immense opportunities for the growth and adoption of sleep apnea devices, therefore will this scenario continue in the next five years?

Where will all the advancements in technology offered by various companies take the industry in the mid to long term?

What are the upcoming alternative therapies and devices related to the same in the sleep apnea devices market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst